Article Details
Retrieved on: 2022-12-28 08:13:51
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
AstraZeneca announced on Wednesday that its immunotherapies 'Imfinzi', or durvalumab, and 'Imjudo', or tremelimumab, have been approved in Japan ...
Article found on: www.sharecast.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here